ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Medenica Trial Begins In South Carolina

February 10, 1995

Turmoil in Texas: Texas Agency Funded $11 Million Grant Without Peer Review; Official Resigns

November 30, 2012

FDA Committee to Discuss Policy On Combinations

January 7, 1977

Clinical Research; Duke Received Several Warnings from OPRR, Letters Indicate

May 14, 1999

In Brief: Beahrs, Murphy, Quan Honored By SSO; AACR Award Mulligan, Wiggler, Sporn, Witte

March 29, 1991

NCI Stops Trial Of Screening In Men To Add Women

November 2, 1990